Literature DB >> 15855749

Rifaximin: in vitro and in vivo antibacterial activity--a review.

Z D Jiang1, H L DuPont.   

Abstract

In vitro inhibitory activity of rifaximin is directed against Gram-positive and Gram-negative, aerobic and anaerobic bacteria. It is effective in the treatment of gastrointestinal infections when given orally because of the high concentration of the drug remaining in the gut lumen. Laboratory investigations have been carried out to assess the in vitro activity of rifaximin on different bacterial strains isolated from both human and domestic animals. The objective of this project is to review the in vitro and in vivo activity of rifaximin against bacterial infection with Gram-negative rods, Gram-positive rods and Gram-positive cocci and their resistance to rifaximin. The available data suggest that rifaximin is active in vitro and in vivo in the treatment of bacterial infection of adults and children. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855749     DOI: 10.1159/000081991

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  44 in total

Review 1.  Bacterial Transcription as a Target for Antibacterial Drug Development.

Authors:  Cong Ma; Xiao Yang; Peter J Lewis
Journal:  Microbiol Mol Biol Rev       Date:  2016-01-13       Impact factor: 11.056

2.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 3.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 4.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

5.  Treatment options for covert hepatic encephalopathy.

Authors:  Nisheet Waghray; Abhijeet Waghray; Kevin Mullen
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06

Review 6.  Pathophysiology, diagnosis, and management of hepatic encephalopathy.

Authors:  Christopher Sheasgreen; Lucy Lu; Ameen Patel
Journal:  Inflammopharmacology       Date:  2014-10-10       Impact factor: 4.473

Review 7.  Antibiotics for the treatment of hepatic encephalopathy.

Authors:  Kavish R Patidar; Jasmohan S Bajaj
Journal:  Metab Brain Dis       Date:  2013-02-08       Impact factor: 3.584

Review 8.  Rifaximin: a review of its use in the management of traveller's diarrhoea.

Authors:  Gayle W Robins; Keri Wellington
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  The effect of rifaximin on gut flora and Staphylococcus resistance.

Authors:  Mi-Sung Kim; Walter Morales; Andres Ardila Hani; Sharon Kim; Gene Kim; Stacy Weitsman; Christopher Chang; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2013-04-16       Impact factor: 3.199

10.  Gastrointestinal complications of diabetes mellitus.

Authors:  Babu Krishnan; Shithu Babu; Jessica Walker; Adrian B Walker; Joseph M Pappachan
Journal:  World J Diabetes       Date:  2013-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.